Celgene ($CELG) executives highlight a blockbuster future for the oral psoriasis drug apremilast. But on Saturday, investigators rattled the company's die-hard enthusiasts, noting that new Phase III data fell short of an earlier round that had helped whip up high hopes. Nevertheless, Celgene is on its way to filing for an approval later this year, with good odds of winning a green light from the FDA. Report